Back to top
more

Doximity (DOCS)

(Delayed Data from NYSE)

$57.33 USD

57.33
1,489,205

-1.42 (-2.42%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $57.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses

by Zacks Equity Research

TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.

Debanjana Dey headshot

Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare

by Debanjana Dey

HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.

Zacks Equity Research

Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

Does OptimizeRx Have a Moat in the Crowded HealthTech Space?

by Indrajit Bandyopadhyay

OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?

Zacks Equity Research

OMCL vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

OMCL vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.

Zacks Equity Research

UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs

by Zacks Equity Research

UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.

Zacks Equity Research

Universal Health Q2 Earnings Beat on Strong Acute Care Admissions

by Zacks Equity Research

UHS tops Q2 estimates with EPS up 24% as strong acute care and behavioral admissions drive revenue growth.

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -100.00% and -17.86%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Community Health Q2 Earnings Miss on Declining Patient Days

by Zacks Equity Research

CYH posts Q2 loss despite revenue beat, as patient days and adjusted admissions decline year over year.

Zacks Equity Research

Molina Healthcare Q2 Earnings Miss on Rising Medical Care Costs

by Zacks Equity Research

MOH's Q2 earnings lag estimates as rising medical care costs offset gains from premiums and rate hikes.

Zacks Equity Research

Doximity (DOCS) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Doximity (DOCS) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.

Zacks Equity Research

Doximity (DOCS) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.

Zacks Equity Research

Do Options Traders Know Something About Doximity Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to DOCS stock based on the movements in the options market lately.

Indrajit Bandyopadhyay headshot

OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?

by Indrajit Bandyopadhyay

OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.

Indrajit Bandyopadhyay headshot

OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?

by Indrajit Bandyopadhyay

OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.

Zacks Equity Research

Doximity (DOCS) Laps the Stock Market: Here's Why

by Zacks Equity Research

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.

Indrajit Bandyopadhyay headshot

Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

by Indrajit Bandyopadhyay

DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.

Indrajit Bandyopadhyay headshot

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

by Indrajit Bandyopadhyay

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

Indrajit Bandyopadhyay headshot

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

by Indrajit Bandyopadhyay

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

Zacks Equity Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

AGM vs. ZG: Which Stock Is the Better Value Option?

by Zacks Equity Research

AGM vs. ZG: Which Stock Is the Better Value Option?

Zacks Equity Research

VOYA or SLF: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VOYA vs. SLF: Which Stock Is the Better Value Option?

Zacks Equity Research

BBD vs. HDB: Which Stock Is the Better Value Option?

by Zacks Equity Research

BBD vs. HDB: Which Stock Is the Better Value Option?